There is one other element regarding precautions, and that is time. (None of the animal studies showed elevated levels in salivary glands.) Again, there is no evidence that 223Ra is present in saliva. Saliva on pillows or bedding is not easily transferred from fabric to hand to mouth. I would have no concerns with washing utensils together with other household members in the dishwasher. (Like you said, this is a relatively new radiopharmaceutical treatment.) If there were any 223Ra on utensils, it would be easily removed by washing. It may have been suggested for 223Ra because it seems like a good idea considering past precautions. The advice to use separate utensils is a standard precaution for certain other radiopharmaceutical therapies (e.g., treatment of thyroid disease with 131I) in which elimination routes include saliva and sweat. If you have small kids who play in the toilet water (reminiscent of an old Bill Cosby routine) or pets that use it as a water bowl (I had a dog that would lift the lid to get a drink), then cleaning the bowl after its use might be something to consider. “Flushing twice” is intended to reduce the amount of fecal material and urine that remains after the first flush. Radium-223 is also mostly an internal hazard, that is, the radiation dose from it is much higher when it is in the body than when it is outside of the body.Ĭonsidering the above, good personal hygiene is the key precaution. The first two organs are due to the 223Ra in feces and urine, respectively. Animal studies showed the only soft tissues with raised levels of 223Ra after administration are the intestines, kidneys and spleen. Food and Drug Administration documents containing pharmacokinetics data). I have found no information that it is present in saliva or sweat (including in U.S. Radium-223 is eliminated by the body mainly in feces and urine. Learn more about Dr.Very few precautions are necessary to protect household members from 223Ra and the radiation doses around individuals administered 223Ra are low. He has been honored with multiple awards for his contributions to patient care, clinical research, and medical education. He serves as an oral and written boards examiner for the American Board of Radiology and as an active committee member for the American Society for Radiation Oncology, American Radium Society, SWOG, ECOG-ACRIN, and NRG. He has co-authored over 135 peer-reviewed original research articles and 45 reviews, book chapters, invited editorials, and practice guidelines. He leads a wide-ranging research program in clinical trials, real-world evidence, and health services. Park subspecializes in radiation therapy for lung cancer and head and neck cancer, maintaining a busy clinical practice in New Haven. He completed his internal medicine internship at Harvard Medical School's Beth Israel Deaconess Medical Center before returning to Yale New Haven Hospital for his residency and chief residency in radiation oncology.ĭr. Park received his undergraduate degree from Yale College, master's degree from the Harvard School of Public Health, and medical doctorate degree from the Yale School of Medicine. He has previously held roles as the associate residency program director, medical student electives director, and continuing medical education director for radiation oncology.ĭr. For the medical school's Office of Student Affairs, he is one of six academic advisors and the head of Purple College. For the Yale Cancer Center, he is an assistant medical director of the Clinical Trials Office, through which he leads the radiation oncology committee and is associate leader of the lung clinical research team. Park is a board-certified radiation oncologist who serves as associate professor, vice chair for clinical research, and chief of thoracic radiotherapy for the Department of Therapeutic Radiology at the Yale School of Medicine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |